Estimating the Detection Limit of Spectrofluorometers - Pharmaceutical Technology

Latest Issue
PharmTech

Latest Issue
PharmTech Europe

Estimating the Detection Limit of Spectrofluorometers

A new Certified Reference Material from Starna Scientific allows the ultimate sensitivity of high-performance spectrofluorometers to be estimated. Traditionally, this was tested using very dilute solutions of fluorophores such as Quinine Sulfate. Near the detection limit, however, concentrations are so low that sample preparation becomes difficult, and there is a real risk of contamination.

When excited by UV or visible radiation, water emits a Raman peak that can be readily identified.  Because very few photons are involved in Raman scattering, the signal levels are very low, comparable to those produced by very low analyte concentrations in normal fluorescence measurements. The intensity and signal-to-noise ratio of the Raman signal therefore indicate the ultimate detection limit of the spectrofluorometer.

The reference material is a permanently sealed UV quartz 10mm fluorometer cuvette containing ultra-high purity water, supplied with a Certificate of Validation and full instructions for use. The certificate shows typical Raman spectra measured on a reference spectrophotometer traceable to NIST primary references, and signal-to-noise ratios calculated at two different excitation wavelengths.

Starna Scientific is accredited to ISO Guide 34 and ISO 17025.  Subject to appropriate storage and use, all Starna Certified Reference Materials carry a lifetime guarantee.

Starna Scientific Ltd.
www.starna.com
sales@starna.com
LCGC E-mail Newsletters

Subscribe: Click to learn more about the newsletter
| Weekly
| Monthly
|Monthly
| Weekly

Survey
Which of the following business challenge poses the greatest threat to your company?
Building a sustainable pipeline of products
Attracting a skilled workforce
Obtaining/maintaining adequate financing
Regulatory compliance
Building a sustainable pipeline of products
30%
Attracting a skilled workforce
27%
Obtaining/maintaining adequate financing
14%
Regulatory compliance
30%
View Results
Eric Langer Outsourcing Outlook Eric LangerBiopharma Outsourcing Activities Update
Cynthia Challener, PhD Ingredients Insider Cynthia Challener, PhDAppropriate Process Design Critical for Commercial Manufacture of Highly Potent APIs
Jill Wechsler Regulatory Watch Jill Wechsler FDA and Manufacturers Seek a More Secure Drug Supply Chain
Sean Milmo European Regulatory WatcchSean MilmoQuality by Design?Bridging the Gap between Concept and Implementation
Medicare Payment Data Raises Questions About Drug Costs
FDA Wants You!
A New Strategy to Tackle Antibiotic Resistance
Drug-Diagnostic Development Stymied by Payer Concerns
Obama Administration Halts Attack on Medicare Drug Plans
FindPharma Custom Search

Click here